文献速递血栓与止血

DOAC水平与临床结局的关系:检测值说明问题

The relationship between DOAC levels and clinical outcomes: The measures tell the tale.
PubMed 文献 · J Thromb Haemost · 2020-10-19

直接口服抗凝药(DOAC)以固定剂量用于血栓栓塞性疾病的治疗和预防,尽管安全性和有效性良好,临床事件仍会发生。本文为观点文章,总结现有证据提示DOAC血药浓度与临床结局相关,并建议在极端体重或肾功能受损患者中研究个体化治疗能否改善结局。

要点

  • DOAC以固定剂量用于血栓栓塞性疾病的治疗和预防,临床事件仍可发生。
  • 抗凝治疗是凝血与出血间的平衡,可能存在兼顾最低出血和血栓风险的最佳靶浓度。
  • 现有证据提示基于DOAC水平的个体化治疗可能可行,需在极端体重或肾功能受损患者中研究。

核心结论

  • 现有证据提示基于DOAC水平的个体化治疗策略可能可行,但需在特定患者群体中进一步研究以评估能否改善结局。

研究设计与样本

  • 观点文章,总结现有证据并描述在极端体重或肾功能受损患者中开展研究的建议。

主要发现

  • 维生素K拮抗剂和肝素等其他抗凝药提供了重要线索,提示可能存在兼顾最低出血和血栓风险的最佳抗凝效应靶点。

临床怎么用

  • 作者建议在极端体重或肾功能受损患者群体中开展研究,评估基于DOAC水平的个体化治疗能否带来更好的患者结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Direct oral anticoagulants (DOACs) are increasingly used for treatment and prevention of thromboembolic diseases, used in fixed dose regimens. Although their safety and efficacy profiles are considered optimal, clinical events still occur. Given that anticoagulation treatment is a delicate balance between clotting and bleeding, it is possible that an optimal target spot exists where the effect of anticoagulation achieves both the lowest possible risk of bleeding and thrombosis. Other currently available anticoagulants (ie, vitamin K antagonists and heparins) provide important clues for this. If such a target spot exists, tailored DOAC therapy may further benefit patients. This opinion article summarizes the current available evidence that suggests that such a tailored strategy could work. It also describes research suggestions for conducting studies in patient populations such as patients with extremes of body weight or impaired kidney function to evaluate whether tailored treatment with DOACs could lead to better patient outcomes.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Toorop MMA, Lijfering WM, Scheres LJJ, et al. The relationship between DOAC levels and clinical outcomes: The measures tell the tale. J Thromb Haemost. 2020. PMID: 32979033. doi:10.1111/jth.15104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。